[
  {
    "ts": null,
    "headline": "Buy These 5 Price-to-Book Value Stocks in November",
    "summary": "The P/B ratio helps to identify low-priced stocks with high growth prospects. PFE, GM, GBX, ITRI and STNE are some such stocks.",
    "url": "https://finnhub.io/api/news?id=5bb5754f8f3ea5cbc3ec78d49bd6fb6f54b67372c9a7214633dea920d2e7fe02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731528000,
      "headline": "Buy These 5 Price-to-Book Value Stocks in November",
      "id": 131335134,
      "image": "https://media.zenfs.com/en/zacks.com/7a485d2e2ad61d332c29428365edb6dc",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The P/B ratio helps to identify low-priced stocks with high growth prospects. PFE, GM, GBX, ITRI and STNE are some such stocks.",
      "url": "https://finnhub.io/api/news?id=5bb5754f8f3ea5cbc3ec78d49bd6fb6f54b67372c9a7214633dea920d2e7fe02"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) UBS Global Healthcare Conference (Transcript)",
    "summary": "Pfizer Inc. (NYSE:PFE) UBS Global Healthcare Conference November 13, 2024 3:30 PM ETCompany ParticipantsAamir Malik - Chief Commercial Officer USConference...",
    "url": "https://finnhub.io/api/news?id=ac309dfa249cb104b5c1d40ee274c672d557ccb0c3e2f3f392835aff851e56cf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731525787,
      "headline": "Pfizer Inc. (PFE) UBS Global Healthcare Conference (Transcript)",
      "id": 131336712,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. (NYSE:PFE) UBS Global Healthcare Conference November 13, 2024 3:30 PM ETCompany ParticipantsAamir Malik - Chief Commercial Officer USConference...",
      "url": "https://finnhub.io/api/news?id=ac309dfa249cb104b5c1d40ee274c672d557ccb0c3e2f3f392835aff851e56cf"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=efbea7c3b1d8481ca9d5cb4619f6c7db934db3da427ed01b138a4d51d5128db0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731515940,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 131416305,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=efbea7c3b1d8481ca9d5cb4619f6c7db934db3da427ed01b138a4d51d5128db0"
    }
  },
  {
    "ts": null,
    "headline": "Q3 2024 Sangamo Therapeutics Inc Earnings Call",
    "summary": "Q3 2024 Sangamo Therapeutics Inc Earnings Call",
    "url": "https://finnhub.io/api/news?id=04de4771fad86b39c6d62364c079d968e4aa532fd31f4170946b5f08eb24b8aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731509352,
      "headline": "Q3 2024 Sangamo Therapeutics Inc Earnings Call",
      "id": 131326151,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Q3 2024 Sangamo Therapeutics Inc Earnings Call",
      "url": "https://finnhub.io/api/news?id=04de4771fad86b39c6d62364c079d968e4aa532fd31f4170946b5f08eb24b8aa"
    }
  },
  {
    "ts": null,
    "headline": "Down -11.04% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)",
    "summary": "Pfizer (PFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.",
    "url": "https://finnhub.io/api/news?id=b9852aa8febc64d98090248846dfd93e42db7a25e1207189d1a9790371f31f84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731508506,
      "headline": "Down -11.04% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)",
      "id": 131327020,
      "image": "https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.",
      "url": "https://finnhub.io/api/news?id=b9852aa8febc64d98090248846dfd93e42db7a25e1207189d1a9790371f31f84"
    }
  },
  {
    "ts": null,
    "headline": "There May Be Some Bright Spots In Pfizer's (NYSE:PFE) Earnings",
    "summary": "The market for Pfizer Inc.'s ( NYSE:PFE ) shares didn't move much after it posted weak earnings recently. Our analysis...",
    "url": "https://finnhub.io/api/news?id=e7aff449d3130a701d66f6900c3a8e2165487775b5ffe6e49d949615130af230",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731492644,
      "headline": "There May Be Some Bright Spots In Pfizer's (NYSE:PFE) Earnings",
      "id": 131326152,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/8f018d189c2c443014c49845310ae091",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The market for Pfizer Inc.'s ( NYSE:PFE ) shares didn't move much after it posted weak earnings recently. Our analysis...",
      "url": "https://finnhub.io/api/news?id=e7aff449d3130a701d66f6900c3a8e2165487775b5ffe6e49d949615130af230"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer considers divestiture of hospital drugs business",
    "summary": "The segment generates EBITDA of roughly $500m at present.",
    "url": "https://finnhub.io/api/news?id=f06351b42b6ba97b0194b57846c7377ab58e666d6347f511d0bd9d0125094f38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731490610,
      "headline": "Pfizer considers divestiture of hospital drugs business",
      "id": 131326153,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/11/Pharma-1-Pfizer_HQ_Entrance.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The segment generates EBITDA of roughly $500m at present.",
      "url": "https://finnhub.io/api/news?id=f06351b42b6ba97b0194b57846c7377ab58e666d6347f511d0bd9d0125094f38"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Tracking Well Above The Industry",
    "summary": "Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating from financial writer. Read more here.",
    "url": "https://finnhub.io/api/news?id=b93cf744417e6816b73bb9510095e2913406cda0e8427554ff425e4123bc4232",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731489024,
      "headline": "Johnson & Johnson: Tracking Well Above The Industry",
      "id": 131324406,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413108793/image_1413108793.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating from financial writer. Read more here.",
      "url": "https://finnhub.io/api/news?id=b93cf744417e6816b73bb9510095e2913406cda0e8427554ff425e4123bc4232"
    }
  },
  {
    "ts": null,
    "headline": "Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...",
    "summary": "Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding challenges.",
    "url": "https://finnhub.io/api/news?id=14cb104bbf899eda0eb49c70d3aaf491f669408321a407ff1ecdab17f02a639b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731482214,
      "headline": "Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...",
      "id": 131320093,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/495665872de6cf4730170a0388bbd4fb",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding challenges.",
      "url": "https://finnhub.io/api/news?id=14cb104bbf899eda0eb49c70d3aaf491f669408321a407ff1ecdab17f02a639b"
    }
  },
  {
    "ts": null,
    "headline": "Zacks.com featured highlights include StoneCo, Skechers, Pfizer and General Motors",
    "summary": "StoneCo, Skechers, Pfizer and General Motors have been highlighted in this Screen of The Week article.",
    "url": "https://finnhub.io/api/news?id=9f820cda9c0cc2dbd92f69eb4f586e05afa3081902554e12266f05a97d3098b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731482100,
      "headline": "Zacks.com featured highlights include StoneCo, Skechers, Pfizer and General Motors",
      "id": 131320179,
      "image": "https://media.zenfs.com/en/zacks.com/cf9e8a6436d7464a37bf01a1eac217af",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "StoneCo, Skechers, Pfizer and General Motors have been highlighted in this Screen of The Week article.",
      "url": "https://finnhub.io/api/news?id=9f820cda9c0cc2dbd92f69eb4f586e05afa3081902554e12266f05a97d3098b5"
    }
  }
]